title: Ibuprofen-in-cyclodextrin-in-W/O/W emulsion - Improving the initial and long-term encapsulation efficiency of a model active ingredient.
abstract: A challenge in formulating water-in-oil-in-water (W/O/W) emulsions is the uncontrolled release of the encapsulated compound prior to application. Pharmaceuticals and nutraceuticals usually have amphipathic nature, which may contribute to leakage of the active ingredient. In the present study, cyclodextrins (CyDs) were used to impart a change in the relative polarity and size of a model compound (ibuprofen) by the formation of inclusion complexes. Various inclusion complexes (2-hydroxypropyl (HP)-β-CyD-, α-CyD- and γ-CyD-ibuprofen) were prepared and presented within W/O/W emulsions, and the initial and long-term encapsulation efficiency was investigated. HP-β-CyD-ibuprofen provided the highest encapsulation of ibuprofen in comparison to a W/O/W emulsion with unassociated ibuprofen confined within the inner water phase, with a four-fold increase in the encapsulation efficiency. An improved, although lower, encapsulation efficiency was obtained for the inclusion complex γ-CyD-ibuprofen in comparison to HP-β-CyD-ibuprofen, whereas α-CyD-ibuprofen had a similar encapsulation efficiency to that of unassociated ibuprofen. The lower encapsulation efficiency of ibuprofen in combination with α-CyD and γ-CyD was attributed to a lower association constant for the γ-CyD-ibuprofen inclusion complex and the ability of α-CyD to form inclusion complexes with fatty acids. For the W/O/W emulsion prepared with HP-β-CyD-ibuprofen, the highest encapsulation of ibuprofen was obtained at hyper- and iso-osmotic conditions and by using an excess molar ratio of CyD to ibuprofen. In the last part of the study, it was suggested that the chemical modification of the HP-β-CyD molecule did not influence the encapsulation of ibuprofen, as a similar encapsulation efficiency was obtained for an inclusion complex prepared with mono-1-glucose-β-CyD.
authors.affiliation: Department of Biotechnology, Norwegian University of Science and Technology (NTNU), N-7491 Trondheim, Norway; ConCordix Pharma, N-9008 Tromsø, Norway. Electronic address: magnus.n.hattrem@ntnu.no.
authors.forename: Magnus N
authors.initials: MN
authors.lastname: Hattrem
authors.affiliation: Department of Biotechnology, Norwegian University of Science and Technology (NTNU), N-7491 Trondheim, Norway. Electronic address: kare.a.kristiansen@ntnu.no.
authors.forename: Kåre A
authors.initials: KA
authors.lastname: Kristiansen
authors.affiliation: Department of Biotechnology, Norwegian University of Science and Technology (NTNU), N-7491 Trondheim, Norway. Electronic address: finn.l.aachmann@ntnu.no.
authors.forename: Finn L
authors.initials: FL
authors.lastname: Aachmann
authors.affiliation: Department of Biotechnology, Norwegian University of Science and Technology (NTNU), N-7491 Trondheim, Norway. Electronic address: morten.j.dille@ntnu.no.
authors.forename: Morten J
authors.initials: MJ
authors.lastname: Dille
authors.affiliation: Department of Biotechnology, Norwegian University of Science and Technology (NTNU), N-7491 Trondheim, Norway. Electronic address: kurt.i.draget@ntnu.no.
authors.forename: Kurt I
authors.initials: KI
authors.lastname: Draget
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D003505:Cyclodextrins; D004339:Drug Compounding; D004356:Drug Storage; D004655:Emulsions; D008401:Gas Chromatography-Mass Spectrometry; D007052:Ibuprofen / Q000008:administration & dosage*; D009821:Oils / Q000737:chemistry; D014867:Water / Q000737:chemistry
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003505:Cyclodextrins; D004655:Emulsions; D009821:Oils; D014867:Water; D007052:Ibuprofen
keywords: Cyclodextrin; Drug delivery; Encapsulation; Inclusion complex; W/O/W emulsion